Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2fc8c4f23758df7ed658973e2a913e38 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5258 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16023 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-6075 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16034 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16134 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-14123 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-14134 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-24134 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-62 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-385 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-01 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-62 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-385 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-49 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-16 |
filingDate |
2018-12-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b396288765a0e172e2af3c388956ed96 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_029fd28f17b0eb53226f557279371bbb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4fc406543f55a51e812cd2b46a9cae87 |
publicationDate |
2020-11-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
CN-111918880-A |
titleOfInvention |
Ebola virus and Marburg virus glycoprotein mucin-like domain replacement expression systems for use as a new vaccine approach |
abstract |
We have developed a series of Ebola virus envelope glycoprotein (EboGP)-based chimeric fusion proteins that are still capable of maintaining efficient EboGP in various cell types including human antigen presenting cells (APCs) Mediated viral entry while presenting large viral peptides at the tip, such as the HIV‑Env v3‑v5 domain (up to 241aa) and flanking each EboGP monomer, elicits a robust host immune response. The present invention demonstrates the feasibility of EboGP-based chimeric fusion technology as a novel vaccine approach against different microbial pathogens, including microbial progenitors in humans and animals, and against cancer. |
priorityDate |
2017-12-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |